Essais liés10clinical trials
VillePorto Alegrelocalisation
PaysBrazillocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06152575

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
Giredestrant Cancer Phase 3 NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) ACTIVE_NOT_RECRUITING
ACP-204 Alzheimer Phase 2/3 NCT06159673 ACP-204 in Adults With Alzheimer's Disease Psychosis RECRUITING
Elranatamab Cancer Phase 3 NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) RECRUITING
ACP-204 Alzheimer Phase 3 NCT06194799 ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study ENROLLING_BY_INVITATION
Trontinemab Alzheimer Phase 3 NCT07169578 TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease RECRUITING
Nipocalimab Lupus Phase 3 NCT07438496 GARDENIA-SLE — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus RECRUITING
Litifilimab Lupus Phase 2/3 NCT05531565 AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus ACTIVE_NOT_RECRUITING
Litifilimab Lupus Phase 3 NCT05352919 EMERALD — An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus ENROLLING_BY_INVITATION
Xanomeline/Trospium Chloride Capsule Alzheimer Phase 3 NCT07011732 A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) RECRUITING
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING